As of the end of February, 785 subjects have been enrolled into the EVADE study of which 143 have been randomized.
Thanks to several booster activities – such as the distribution of the patient profile of already randomized patients, the organization of a rejuvenation meeting in June 2018, a protocol amendment, and of course continued communication with all sites – the average number of randomizations per month has increased from 3-4 per month early 2018 to 6-7 in the past 6 months, with a record of 11 randomizations in February 2019.
Currently, there are 75 active sites in the following countries: Austria, Belgium, Croatia, Czech Republic, France, Greece, Hungary, Ireland, Israel, Portugal, Spain, Turkey, UK, and US. 74 of these 75 sites have actively screened at least 1 patient and 42 have randomized at least 1 patient.
Congratulations go to the sites of Dr Richard (APHP Hôpital de Bicêtre, France), Dr Wyncoll (St. Thomas’ Hospital, UK), Dr Vazquez (Augusta University, US), Dr Plantefève (Centre Hospitalier Victor Dupouy Argenteuil, France), Dr Hopkins (King’s College Hospital, UK), Dr Joannidis (Medical University of Innsbruck, Austria), Dr Klouche (CHU de Montpellier/ Lapeyronie hospital, France) and Dr Jaber (CHU de Montpellier/ St Eloi hospital, France), who have all randomized their first patient in the past months.
The team would also would like to thank all other sites for their continued efforts, considering the big data cleaning effort in preparation of the independent adjudication process, planned to start soon.
EVADE Database Lock: Central Laboratory Data
EVADE Finalizes Database Lock
EPI-Net's Collaboration with the JPIAMR ARCH/GAP-ON€ Projects
COMBACTE-MAGNET’s EPI-Net collaboration with JPIAMR ARCH/GAP-ON€ projects: a translational approach to bridge the gaps between surveillance and ...